Ashford Capital Management Inc. decreased its position in shares of Incyte Co. (NASDAQ:INCY) by 1.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 99,318 shares of the biopharmaceutical company’s stock after selling 1,690 shares during the quarter. Incyte makes up 1.5% of Ashford Capital Management Inc.’s holdings, making the stock its 26th largest holding. Ashford Capital Management Inc.’s holdings in Incyte were worth $9,406,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Sands Capital Management LLC grew its position in shares of Incyte by 8.2% during the 4th quarter. Sands Capital Management LLC now owns 8,191,287 shares of the biopharmaceutical company’s stock worth $775,797,000 after buying an additional 621,323 shares in the last quarter. Capital International Investors grew its position in shares of Incyte by 1.4% during the 3rd quarter. Capital International Investors now owns 6,494,566 shares of the biopharmaceutical company’s stock worth $758,176,000 after buying an additional 87,369 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Incyte by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 1,938,238 shares of the biopharmaceutical company’s stock worth $183,205,000 after buying an additional 105,692 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Incyte by 0.4% during the 4th quarter. Bank of New York Mellon Corp now owns 1,682,019 shares of the biopharmaceutical company’s stock worth $159,304,000 after buying an additional 7,463 shares in the last quarter. Finally, HealthCor Management L.P. grew its position in shares of Incyte by 125.5% during the 4th quarter. HealthCor Management L.P. now owns 1,350,000 shares of the biopharmaceutical company’s stock worth $127,859,000 after buying an additional 751,450 shares in the last quarter. 93.56% of the stock is currently owned by institutional investors and hedge funds.
In other news, insider David W. Gryska sold 6,760 shares of the firm’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $98.87, for a total value of $668,361.20. Following the completion of the transaction, the insider now directly owns 20,752 shares in the company, valued at $2,051,750.24. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Vijay K. Iyengar sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $97.26, for a total value of $486,300.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 15,670 shares of company stock valued at $1,489,181. Company insiders own 17.70% of the company’s stock.
A number of equities research analysts recently weighed in on INCY shares. Nomura reaffirmed a “buy” rating on shares of Incyte in a research report on Thursday, February 1st. BMO Capital Markets reaffirmed a “buy” rating and set a $172.00 price objective on shares of Incyte in a research report on Wednesday, January 3rd. TheStreet downgraded Incyte from a “c-” rating to a “d+” rating in a research report on Tuesday, December 5th. Royal Bank of Canada dropped their price objective on Incyte from $136.00 to $120.00 and set a “sector perform” rating on the stock in a research report on Tuesday, November 21st. Finally, ValuEngine raised Incyte from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. Two analysts have rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $142.83.
Incyte Co. (NASDAQ INCY) opened at $86.27 on Tuesday. Incyte Co. has a 12 month low of $80.85 and a 12 month high of $149.00. The stock has a market capitalization of $19,068.24, a PE ratio of -55.30 and a beta of 0.65. The company has a quick ratio of 3.99, a current ratio of 4.01 and a debt-to-equity ratio of 0.01.
Incyte (NASDAQ:INCY) last announced its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.54. Incyte had a negative return on equity of 11.85% and a negative net margin of 20.38%. The firm had revenue of $444.20 million during the quarter, compared to analysts’ expectations of $435.23 million. During the same period last year, the business posted $0.05 earnings per share. The company’s revenue for the quarter was up 36.0% compared to the same quarter last year. research analysts anticipate that Incyte Co. will post -0.28 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Ashford Capital Management Inc. Sells 1,690 Shares of Incyte Co. (INCY)” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://ledgergazette.com/2018/03/20/ashford-capital-management-inc-sells-1690-shares-of-incyte-co-incy.html.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.